Mandate

Vinge advises on Medivir’s new issue

March 29, 2010

Medivir AB (publ) (NASDAQ OMX Stockholm) is performing a rights issue for approximately SEK 300 million. The new issue is fully covered by subscription undertakings, declarations of intent and underwriting undertakings from, among others, Carnegie and Jefferies acting as Joint Bookrunners.

Vinge is advising Medivir. Vinge’s team consists of Erik Sjöman, Emil Hedberg and Jesper Schönbeck. In addition, Rikard Stenberg, Maria Doeser and Markus Larsson have been involved in the transaction.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026